[CAS NO. 113665-84-2]  Clopidogrel

Ships within Stock Price Qty Total
$0.00
$0.00
Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis
request a quote
If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [113665-84-2]

Catalog
HY-15283
Brand
MCE
CAS
113665-84-2

DESCRIPTION [113665-84-2]

Overview

MDLMFCD05662337
Molecular Weight321.82
Molecular FormulaC16H16ClNO2S
SMILESClC1=C(C=CC=C1)[C@H](N2CCC3=C(C2)C=CS3)C(OC)=O

For research use only. We do not sell to patients.


Summary

Clopidogrel is an orally active platelet inhibitor that targets P2Y12 receptor. Clopidogrel is used to inhibit blood clots in coronary artery disease, peripheral vascular disease, and cerebrovascular disease.


IC50 & Target

P2Y12 receptor [1] .


In Vivo

Clopidogrel, administered during the last three months, significantly decreases blood glucose, collagen and fibronectin expression compared to vehicle-treated diabetic mice. Clopidogrel markedly ameliorates hyperglycemia-induced renal fibrosis [1] . The combination therapy of clopidogrel and aspirin (dual-antiplatelet therapy) has been shown to be significantly beneficial compared to aspirin monotherapy and has also shown to decrease sub-acute stent thrombosis as well as recurrent ischemic events following ACS [2] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.


Clinical Trial

NCT Number Sponsor Condition Start Date Phase
NCT02052635 AstraZeneca
Non-ST Elevation Acute Coronary Syndrome
September 2014 Phase 4
NCT00661206 Deutsches Herzzentrum Muenchen
Coronary Artery Disease
September 2008 Phase 4
NCT04069234 Region Skane|IHF GmbH - Institut für Herzinfarktforschung|Hippocrates Research|IRW consulting AB|AstraZeneca
Diabetes Mellitus|Microvascular Coronary Artery Disease
September 15, 2019 Phase 3

Appearance

Oil


Shipping

Room temperature in continental US; may vary elsewhere.


Storage

-20°C, stored under nitrogen, away from moisture

* In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen, away from moisture)


Solvent & Solubility

In Vitro:

DMSO : 50 mg/mL ( 155.37 mM ; Need ultrasonic)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 3.1073 mL 15.5366 mL 31.0733 mL
5 mM 0.6215 mL 3.1073 mL 6.2147 mL
10 mM 0.3107 mL 1.5537 mL 3.1073 mL
* Please refer to the solubility information to select the appropriate solvent.
In Vivo:
  • 1.

    Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline

    Solubility: ≥ 2.5 mg/mL (7.77 mM); Clear solution

  • 2.

    Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)

    Solubility: ≥ 2.5 mg/mL (7.77 mM); Clear solution

  • 3.

    Add each solvent one by one: 10% DMSO >> 90% corn oil

    Solubility: 2.5 mg/mL (7.77 mM); Suspended solution; Need ultrasonic

* All of the co-solvents are available by MCE.


Synonyms

Thieno[3,2-c]pyridine-5(4H)-acetic acid, α-(2-chlorophenyl)-6,7-dihydro-, methyl ester, (αS)-
Thieno[3,2-c]pyridine-5(4H)-acetic acid, α-(2-chlorophenyl)-6,7-dihydro-, methyl ester, (S)-
Clopidogrel
(S)-(+)-Methyl (2-chlorophenyl)(6,7-dihydro-4H-thieno[3,2-c]pyrid-5-yl)acetate
(S)-Methyl α-(4,5,6,7-tetrahydrothieno[3,2-c]pyridin-5-yl)-α-(o-chlorophenyl)acetate
SR 25990
(S)-Clopidogrel
(+)-(S)-Clopidogrel
Methyl (2S)-(2-chlorophenyl)(6,7-dihydrothieno[3,2-c]pyridin-5(4H)-yl)acetate
R 130964
Thrombo